BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22774570)

  • 1. [The performance of the automated immune chemiluminescent system "IMMULITE 2000XPi for the measurement of serum soluble IL-2 receptor in clinical samples].
    Watanabe N; Nagatomo R; Okubo S; Yokota H; Masuda A; Ikeda H; Yatomi Y
    Rinsho Byori; 2012 May; 60(5):422-8. PubMed ID: 22774570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
    Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
    Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
    Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
    Xu J; Wang B
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
    Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
    Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
    Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
    Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
    Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
    Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
    Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma.
    Kitai R; Sasaki H; Matsuda K; Tsunetoshi K; Yamauchi T; Neishi H; Matsumura K; Tsunoda A; Takeuchi H; Sato K; Kikuta K
    Brain Tumor Pathol; 2013 Jan; 30(1):34-9. PubMed ID: 22399193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M; Darwish NA; Abdel-Aziz O
    J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
    Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Measurement of five cytokines in the serum of malignant lymphoma patients].
    Zhu H; Wang Y; Han X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble interleukin-2 receptor in stage I-III melanoma.
    Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
    Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.